Jyong Biotech (NASDAQ:MENS) Shares Down 2.2% – What’s Next?

Jyong Biotech Ltd. (NASDAQ:MENS) shares traded down 2.2% during mid-day trading on Wednesday. The company traded as low as $1.66 and last traded at $1.74. 83,211 shares changed hands during trading, an increase of 88% from the average daily volume of 44,258 shares. The stock had previously closed at $1.78.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Jyong Biotech in a report on Wednesday, August 19th. One investment analyst has rated the stock with a Sell rating. According to MarketBeat.com, Jyong Biotech presently has an average rating of “Sell”.

Jyong Biotech Trading Up 9.1%

The company’s 50-day moving average is $2.03 and its 200 day moving average is $2.13.

Institutional Inflows and Outflows

An institutional investor recently bought a new stake in Jyong Biotech stock. StoneX Group Inc. acquired a new position in Jyong Biotech Ltd. (NASDAQ:MENS) during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The fund acquired 15,248 shares of the company’s stock, valued at approximately $33,000.

About Jyong Biotech

Jyong Biotech is a China-based biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies for urological diseases. The company’s research approach includes developing drug candidates derived from natural products and traditional Chinese medicine.

Its development pipeline is centered on treatments for conditions affecting the urinary and male reproductive systems, including benign prostatic hyperplasia. Jyong Biotech is a clinical-stage company, and its primary activities include pharmaceutical research, clinical development and the evaluation of potential products for future commercialization.

The company serves the pharmaceutical and healthcare markets in China and is seeking to develop therapies with broader commercial potential.